Noel Hurley joins Bodle as Non-Executive Director

Noel Hurley image

Arm executive Noel Hurley joins Bodle as Non-Executive Director

Bodle Technologies Ltd, an Oxford company set on transforming digital display screens with its reflective display technology SRD® welcomes Noel Hurley of Arm as Non-Executive Director.

Hurley, VP of Strategy for IP Products Group at Arm, is focused on new growth opportunities for disruptive technologies. He has held many senior positions at Arm, including VP and General Manager of the Business Segment Group and General Manager of the CPU Group, where he was responsible for the Arm Cortex Processors.

Hurley was an early employee at Arm, joining initially in 1994. He left the company in 2005 to cofound XMOS Semiconductors, a VC funded fabless semiconductor company. In 2010, he joined Toumaz Technology, becoming COO, before re-joining Arm at the end of 2011.

By providing vivid colour and video-capabilities, with zero energy usage for static image display, Bodle’s unique technology is poised to address numerous screen-related challenges including poor outdoor readability and battery drain due to the high-power consumption inherent in transmissive and emissive displays.

“Noel brings a wealth of experience to Bodle and his decision to join the board is a testament the capabilities our unique technology has to offer,” comments Mike Clary, CEO of Bodle Technologies. “His understanding of embeddable tech will help us transform exciting prototypes into real-world products that could change the face of digital display manufacture.”

Bodle’s Executive Chairman, Dr David Fyfe, retired from the Board on 31st December 2018.

Since co-founding Bodle along with Professor Harish Bhaskaran and Dr Peiman Hosseini in November 2015, Dr Fyfe has taken the company from a laboratory project spin out from the Department of Materials at the University of Oxford to an exciting position at the forefront of new screen display technologies. Dr Fyfe has led the company through two rounds of early stage funding from investors, including Oxford Sciences Innovation, Parkwalk Advisors and Woodford Patient Capital Trust.

Through his leadership, Bodle established a focus on customer-driven innovation and professionalism, and the Board looks forward to his continued support as a significant shareholder in the company.

The Board acknowledges and thanks Dr Fyfe for his unique contribution and guidance during the early years of the company’s life and his pivotal role in setting it onto the road to success.